Literature DB >> 8423096

An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan.

M Ogata1, T Matsumoto, K Koga, I Takenaka, M Kamochi, T Sata, S Yoshida, A Shigematsu.   

Abstract

We found that carrageenan (CAR), that is, sulfated polygalactose, can enhance both lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF) production and the rate of lethality in mice (M. Ogata, S. Yoshida, M. Kamochi, A. Shigematsu, and Y. Mizuguchi, Infect. Immun. 59:679-683, 1991). It has been reported that platelet-activating factor (PAF) antagonists reduce the rate of mortality from endotoxin shock. However, there are few reports regarding the effect of PAF antagonists on TNF production. The aim of the present study is to examine the effect of TCV-309, a new PAF antagonist, on LPS-induced TNF production and mortality in mice pretreated with CAR. ddY mice (6 to 7 weeks old) were injected intraperitoneally with CAR (5 mg per mouse) and were then divided into two groups: mice treated with a PAF antagonist (TCV-309; Takeda Pharmaceutical Co.) and control mice. The mice treated with PAF antagonist received indicated doses of TCV-309 subcutaneously (s.c.) at 30 min before LPS injection, while the control mice received 1 ml of saline s.c. at the same time. All mice were stimulated by intravenous injection of LPS (50 micrograms per mouse) at 24 h after pretreatment with CAR. At intervals after injection of LPS, serum samples were obtained for a TNF assay in which cytotoxicity to L929 cells was measured. TCV-309 both significantly suppressed LPS-induced TNF production and reduced mortality in a dose-dependent manner. When TCV-309 was administered at 30 min before injection of LPS, the effect of TCV-309 on the suppression of TNF activity was at its peak. Treatment with TCV-309 (990 micrograms per mouse) s.c. significantly improved the survival rate after challenge with LPS compared with the survival rate of control mice. Although the 50% lethal dose of LPS was 15 micrograms per mouse for control mice, it increased to 102 micrograms per mouse for mice that were treated s.c. with TCV-309 (990 micrograms per mouse). Even in vitro, TCV-309 also inhibited LPS-induced TNF production in thioglycolate-elicited macrophages. It was concluded that PAF plays an important role in endotoxin-induced TNF production and mortality.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8423096      PMCID: PMC302782          DOI: 10.1128/iai.61.2.699-704.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Multiple-organ-failure syndrome.

Authors:  C J Carrico; J L Meakins; J C Marshall; D Fry; R V Maier
Journal:  Arch Surg       Date:  1986-02

2.  Is platelet activating factor (PAF) a mediator of endotoxin shock?

Authors:  Z Terashita; Y Imura; K Nishikawa; S Sumida
Journal:  Eur J Pharmacol       Date:  1985-02-26       Impact factor: 4.432

3.  Purification and physico-chemical characterization of rabbit tumor necrosis factor.

Authors:  M R Ruff; G E Gifford
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

4.  Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone.

Authors:  T W Doebber; M S Wu; J C Robbins; B M Choy; M N Chang; T Y Shen
Journal:  Biochem Biophys Res Commun       Date:  1985-03-29       Impact factor: 3.575

5.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

6.  Galactosamine-induced sensitization to the lethal effects of endotoxin.

Authors:  C Galanos; M A Freudenberg; W Reutter
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

7.  Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin.

Authors:  F Gonzalez-Crussi; W Hsueh
Journal:  Am J Pathol       Date:  1983-07       Impact factor: 4.307

8.  Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1.

Authors:  M P Bevilacqua; J S Pober; G R Majeau; W Fiers; R S Cotran; M A Gimbrone
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

9.  Protective effect of a selective leukotriene antagonist in endotoxemia in the rat.

Authors:  J A Cook; W C Wise; P V Halushka
Journal:  J Pharmacol Exp Ther       Date:  1985-11       Impact factor: 4.030

10.  Multiple-organ failure. Generalized autodestructive inflammation?

Authors:  R J Goris; T P te Boekhorst; J K Nuytinck; J S Gimbrère
Journal:  Arch Surg       Date:  1985-10
View more
  8 in total

1.  Role for intracellular platelet-activating factor in the circulatory failure in a model of gram-positive shock.

Authors:  S J De Kimpe; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

2.  Carrageenan primes leukocytes to enhance lipopolysaccharide-induced tumor necrosis factor alpha production.

Authors:  M Ogata; T Matsui; T Kita; A Shigematsu
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

3.  A protective role of platelet-activating factor in murine candidiasis.

Authors:  S Y Im; J H Choi; H M Ko; S J Han; S B Chun; H K Lee; T Y Ha
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

4.  Effect of peripheral benzodiazepine receptor ligands on lipopolysaccharide-induced tumor necrosis factor activity in thioglycolate-treated mice.

Authors:  T Matsumoto; M Ogata; K Koga; A Shigematsu
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

5.  The inhibitory effects of allopurinol on the production and cytotoxicity of tumor necrosis factor.

Authors:  T Oláh; K Régely; Y Mándi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-07       Impact factor: 3.000

Review 6.  Strategies to improve drug development for sepsis.

Authors:  Mitchell P Fink; H Shaw Warren
Journal:  Nat Rev Drug Discov       Date:  2014-09-05       Impact factor: 84.694

7.  Binding of lysozyme to lipopolysaccharide suppresses tumor necrosis factor production in vivo.

Authors:  K Takada; N Ohno; T Yadomae
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

Review 8.  Animal models of sepsis.

Authors:  Mitchell P Fink
Journal:  Virulence       Date:  2013-08-19       Impact factor: 5.882

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.